

Executive Management Changes

- ✓ **Dr. Trevor Lockett will cease his executive duties as Technical Director from 15 December 2023 and will continue as a Non-Executive Director;**
- ✓ **Mr. Paul Smith CFO and Joint Company Secretary has resigned for personal reasons, by mutual agreement, with recently appointed Financial Controller Mr. Guy Carisbrooke assuming financial duties;**
- ✓ **Ms. Andrea Steele remains as sole Company Secretary and General Counsel; and**
- ✓ **Executive Search commences for new Chief Executive Officer.**

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) advises that it has instrumented an organisational restructure.

Dr. Trevor Lockett was the initial Managing Director of Rhythm in its IPO in late 2017, will cease his executive position as Technical Director from 15 December 2023, however, will continue as a Non-Executive Director of the Company. Dr Lockett has offered to continue to consult on specific projects as and if required.

Mr. Paul Smith, CFO and Joint Company Secretary has resigned for personal reasons, however, has made his services available as an external consultant to the Company as and if required. Mr Guy Carisbrooke, who joined the company as Financial Controller on 21 September 2023, will assume financial duties.

Ms. Andrea Steele will continue as sole Company Secretary for communications with the ASX in relation to ASX Listing Rule matters.

Further, the Board, has commenced the process to appoint a new Chief Executive Officer. Following a handover period, current Executive Chairman, Mr Otto Buttula, will relinquish his executive duties.

More About...**Mr. Guy Carisbrooke**

Guy Carisbrooke is a seasoned Financial Controller, having successfully steered the finance functions in various companies and sectors, ranging from energy and utilities, health, agriculture, and retail. His educational background is equally robust, boasting two bachelor's degrees and a graduate diploma in Chartered Accountancy (CA). His previous and current responsibilities encompass a wide spectrum, including Board and statutory reporting, project management and implementation, compliance, and customised budgeting and forecasting to align with the business's unique needs and industry standards.

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr. Otto Buttula Executive Chairman	Mr. Guy Carisbrooke Financial Controller	Ms. Andrea Steele General Counsel & Company Secretary
---	--	--

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.